Introduction
In non-malignant prostate epithelial cells control of key histone modifications during vitamin D receptor (VDR)-regulated expression of CDKN1A (encodes p21 (waf1/cip1) ) is spatially controlled across regulatory regions of the gene locus and dynamically regulated in time (1, 2) . The VDR, such as many other nuclear receptors, interacts with coactivators and corepressors during the transcriptional cycle (1) (2) (3) (4) (5) and these interactions combine to determine these highly choreographed distributions of histone modifications. For example, binding of NCOR1 at a specific VDR binding site was associated with the loss of H3K9ac and gain of H3K9me2 and H3K27me3 (2) . In turn, these patterns of corepressor binding and changing histone modifications were associated significantly with key points of messenger RNA (mRNA) oscillation (2) .
These transient histone states also act as platforms to allow effector complexes to regulate other aspects of chromatin architecture such as DNA CpG methylation. For example, gene-repressive histone modifications such as H3K9me2 associate with CpG methylation and heterochromatin. At high-density regions of CpG methylation, spanning hundreds of base pairs, these marks act as triggers to recruit heterochromatin binding protein 1 (6) . The recruitment of heterochromatin binding protein 1 through interaction with the methyl-CpG binding protein MBD1 leads to recruitment of both KMT1A (called previously SUV39H1 (7)) and DNA methyltransferases (8) and thereby the entire region acquires H3K9 and H3K27 methylation and loses H3K4 methylation (reviewed in (9) ). It has also emerged that in actively regulated regions, dynamic changes in DNA methylation appear to occur. For example, these have been measured in response to nuclear receptor actions (10) (11) (12) . In parallel, increased corepressor binding promotes direct association with the DNA methylation-dependent transcriptional repressor ZBTB33/KAISO (13) and targets increased DNA methylation.
Despite these important roles for corepressors to regulate transcription and potentially trigger DNA methylation, they remain somewhat overlooked compared with their coactivator cousins. Ambiguity remains over how and to what extent these actions are distorted in cancer (reviewed in (14) ). The sheer diversity of transcription factor and corepressor interactions contributes significantly to this uncertainty. This is in turn compounded by the fact that there are functionally different corepressor isoforms (15, 16) and that corepressor actions appear specific to each phase of the cell cycle (2, 17, 18) .
Increased NCOR1 and NCOR2/SMRT expression and localization occurs in prostate and other cancers (19) (20) (21) (22) (23) (24) , for example, to suppress VDR and Peroxisome proliferator-activated receptor (PPAR) responsiveness (17, 20, 25) . In contrast, putative loss of function NCOR1 mutations have been identified contributing to breast cancer (26) . The recruitment to the androgen receptor (AR) of corepressors contributes to efficacy of androgen deprivation therapy and consequently loss of expression of NCOR1 and NCOR2/SMRT is also associated with recurrent prostate cancer (27, 28) .
Thus, corepressor expression and interactions appear to change during the course of disease progression. These changes most probably reflect the conflicting selection pressures on corepressor expression, targeting and activity. Set against these uncertainties, dissecting corepressor actions may address the key question of separating epigenetic processes that drive cancer initiation and progression, from those that are merely a consequence of altered genomic structure. This understanding has importance for defining clinical targeting strategies, given that altered corepressor expression generates critical targets for agents that target the regulation of H3K9 acetylation and methylation states. Therefore, the current study aimed to investigate whether corepressor binding was altered in the prostate cancer. Specifically, it focused on two inter-related questions: First, to establish whether corepressor recruitment was altered between prostate cancer (CaP) cell lines that responded differentially toward VDR activation; Second, to reveal how corepressor recruitment was associated with altered DNA methylation patterns. We exploited three prostate cell lines that displayed a range of antiproliferative responses toward 1α,25(OH) 2 D 3 . These were non-malignant RWPE-1 and its RAS-transformed variant, RWPE-2, (29) , and a CaP cell line derived from a metastasis, PC-3 (30 (17, 20, 31, 32) . Therefore, these models are attractive to study the impact of epigenetic events that may be disrupted in the initiation and progression of prostate cancer.
These studies revealed that selective corepressor recruitment was associated with altered patterns of DNA methylation and direct gene transrepression. These differences in corepressor binding and DNA methylation reflected the profound differences in VDR antiproliferative responses in different cell models.
Materials and methods
Cell lines RWPE-1 non-malignant prostate epithelial cells and RWPE-2 cells were maintained in Keratinocyte serum-free medium supplemented with epidermal growth factor and bovine pituitary extract (Invitrogen). PC-3 cells were cultured in RPMI with 10% fetal bovine serum. Quantitative reverse transcription-PCR RNA was isolated using TRizol (Invitrogen). Target gene expression was quantitated on an ABI 7900 (Applied Biosystems, http://www.appliedbiosystems.com) machine. All primers and probes were as described previously (20) . Measurements were performed in technical and biological triplicate.
Multitarget microfluidic quantitative reverse transcription-PCR M
Measurement of multiple gene transcripts was undertaken on custom-designed TaqMan® Low Density Array (ABI 7900HT Fast Real-Time PCR System) as described previously (22) and included known and putative VDR target genes and control genes (31, (33) (34) (35) (36) . mRNA from cell-cycle sorted cells was quantified in triplicate samples measured in duplicate as described previously (17, 22) .
Fold changes were calculated for single target gene expression and statistical analyses were carried out using the TIGR MultiExperiment Viewer 4.0, MeV (www.tm4.org). A one-sample t-test analysis based on permutation (Westfall Young stepdown (37) -MaxT correction) was used to identify genes significantly expressed in each phase of the cell cycle comparing PC-3 to RWPE-1 cells. Vectors containing gene expression values were tested against the mean of 18S fold changes. One-way analysis of variance was used to identify genes that were expressed differentially across the three phases of the cell cycle.
ChIP protocols X-ChIP was used to measure the association of NCOR1 binding as described previously (2, 4) . Briefly, chromatin from 1.5 × 10 6 mid-exponential cells was cross-linked. Precleared inputs were immunoprecipited with NCOR1 (Abcam ab24552). Complexes were recovered using magnetic beads, washed, crosslinking was reversed and further cleared DNA was recovered by standard precipitation approaches. 25 ng DNA was used per quantitative PCR using SYBRgreen with preoptimized primers as described previously (2) .
DNA methylation assays in cell lines
CpG dinucleotide methylation was measured around VDR binding regions and the transcription start site (TSS) of the CDKN1A locus. Specifically, CpG regions in an approximately 300 bp region centered on the VDR binding region were used to undertake MassArray Quantitative Methylation Analysis (MAQMA) on the Sequenome platform in the RPCI Genomics Core Facility as described previously (38) (39) (40) . This approach is high-throughput, with 384 assays performed simultaneously. DNA was isolated from the cells at the indicated time points following treatment. CpG dinucleotide methylation appears to be strand-specific (11) and therefore bisulfite PCR primers specific to each strand were designed for each region of interest.
Results

Suppressed VDR target gene regulation in 1α,25(OH) 2 D 3 -recalcitrant cells
As a functional indicator of 1α,25(OH) 2 D 3 actions, VDR-mediated gene regulatory actions were examined in RWPE-1, RWPE-2 and PC-3 cells. Time-resolved regulation studies were undertaken with three established VDR target genes (VDR, CDKN1A, GADD45A (1, 20, 41) ). The patterns of VDR-mediated gene regulation were selectively distorted in the RWPE-2 and/or PC-3 cells compared with RWPE-1 cells. VDR regulation was distorted most clearly in RWPE-2, being profoundly repressed compared with RWPE-1 at multiple time points (Figure 1 ). The kinetics of CDKN1A mRNA regulation in RWPE-1 cells reflected previous findings (2) , whereas the regulation in RWPE-2 was repressed, for example, at 12 h. Transrepression was evident in PC-3 at multiple time points. In RWPE-1 and RWPE-2 cells, GADD45A also displayed rapid accumulation at 0.5 h and 2 h (RWPE-1 only). Again the fold induction was attenuated significantly in PC-3 cells, for example, at 0.5 h and 6 h ( Figure 1 ). Using a clone of PC-3 cells, we established previously to have stable knock down of NCOR1 (17) and we examined CDKN1A induction following 1α,25(OH) 2 D 3 treatment. In this case, we found that the regulation was significantly enhanced with a loss of the transrepression observed in the parental cells. Interestingly, and probably reflecting some aspect of stable selection, the levels of CDKN1A induction in the vector controls were also beyond the levels seen in RWPE-1 cells ( Figure 2) .
Repression of the VDR mRNA regulation response was also observed when controlling for the impact of the different distributions of cells through the cell cycle in RWPE-1 and PC-3 cells. We noted that in RWPE-1 and PC-3 cells, the regulation of CDKN1A and GADD45A appeared to return to basal levels at 4 h but differed at all time points. Therefore, we selected this time point to examine regulation of genes across the cell cycle. Specifically, a microfluidic quantitative reverse transcription (Q-RT)-PCR M approach (22) was applied to reveal 1α,25(OH) 2 D 3 -regulated expression patterns in cells in each phase of the cell cycle (Table 1 ). Cells in G 1 displayed the greatest differential response between RWPE-1 and PC-3 cells. In G 1 -sorted cells, all VDR targets were regulated positively in RWPE-1 cells but these effects were mostly either reduced or repressed in PC-3 cells in the same phase. This was less pronounced in the other phases with only CYP24A1 and IGFBP3 significantly different in their regulation in all phases. Interestingly, CDKN1A regulation differed significantly in only G 2 /M cells. NCOR2/SMRT, a previously established VDR target gene, was differentially regulated but NCOR1 was not and is not included in the table. Control genes B2M and GAPDH were not regulated differentially among cell lines.
Together these data indicate that gene regulation by 1α,25(OH) 2 D 3 was most dynamic in cells that were most responsive to the antiproliferative effects (RWPE-1 cells). These dynamic patterns included both positive and negative mRNA regulation. Furthermore, cells in G 1 of the cell cycle were the most responsive. By comparison in RWPE-2 and PC-3 cells, the mRNA regulation profiles were increasingly and selectively attenuated. For CDKN1A, at least, NCOR1 appeared to play a significant role in suppressing the accumulation.
Spatial-temporal distribution of NCOR1 to CDKN1A is altered in 1α,25(OH) 2 D 3 -recalcitrant cells
A fine-resolution X-ChIP time course was undertaken to examine NCOR1 recruitment to CDKN1A in cells that were 1α,25(OH) 2 D 3 -sensitive (RWPE-1) and 1α,25(OH) 2 D 3 -recalcitrant (PC-3). 1α,25(OH) 2 D 3 -regulated binding was measured at three VDR binding regions (VDREs 1, 2 and 3) and the TSS on CDKN1A (1) (Figure 3 ).
In the basal state, there were no significant differences between the basal binding of NCOR1 between the two cell models (data not shown). In contrast, following 1α,25(OH) 2 D 3 treatment, the recruitment of NCOR1 differed significantly between the two cell lines. In RWPE-1 cells, there was a pronounced loss of NCOR1 at VDRE3, VDRE2 and the TSS. This trend was significantly reduced in PC-3
Corepressor recruitment in prostate cancer cells where the loss of NCOR1 at VDRE3 did not occur to any significant extent. At specific time points at VDRE2 and VDRE1, NCOR1 enrichment was reciprocal in the two models. Notably at VDRE2 at 0.5 h and at VDRE1 at 12 h and 24 h, NCOR1 was positively enriched in PC-3 cells and lost at the same time point in RWPE-1 cells (Figure 3) . The most extreme inversion of the kinetics of NCOR1 recruitment occurred at the TSS where NCOR1 was lost from this region in RWPE-1 cells but exclusively recruited and enriched in PC-3 cells. These suggest that NCOR1 was recruited differentially to the promoter of CDKN1A, following 1α,25(OH) 2 
Altered histone methyltransferase expression in prostate cancer cells
We next addressed the question as to whether the association of NCOR1 could result in altered DNA methylation at regions adjacent to the VDR binding elements. As a prelude to these studies, we examined the basal expression of several enzymes known to be Fig. 1 . Dynamic regulation of VDR target genes. RWPE-1, RWPE-2 and PC-3 cells were treated with 1α,25(OH) 2 D 3 (100 nM) or ethanol control and mRNA was extracted at the indicated time points, and accumulation of indicated genes was measured using TaqMan Q-RT-PCR. Accumulation of each target is given as log 2 (fold change). Each data point represented the mean of triplicate experiments in triplicate wells ± standard error mean (*P < 0.05, **P < 0.01, ***P < 0.001). Accumulation is given as log 2 (fold change). Each data point represents the mean of triplicate experiments in triplicate wells ± standard error mean (*P < 0.05, **P < 0.01, ***P < 0.001). Exponentially growing RWPE-1 and PC-3 cells were treated with either 1α,25(OH) 2 D 3 (100 nM) or ethanol (control) for 4 h and then fractionated into each phase of the cell cycle prior to mRNA extraction and Q-RT-PCR M to measure regulation of multiple VDR target genes compared with 18S RNA (B2M and GAPDH were included as further controls) and the fold change was transformed into log 2 values. The table is organized to highlight, at the top of the list, genes that changed the most and specifically only those that were significantly modulated. Levels of gene expression are indicated in log 2 fold changes; significance was calculated with a one-sample t-test comparing the expression levels with the value of 0, corresponding to no differences in gene expression between the two cell lines; shaded cell indicates not significant. Association of NCOR1 was measured at each region using X-ChIP with ChIP grade antibodies and normalized and given as fold enrichment over input (2) . Enrichment was measured using Q-PCR with primers specific to these regions that amplified products <150 bp. All measurements were performed in technical duplicate and biological triplicate and are given as log 2 fold enrichment (*P < 0.05, **P < 0.01, ***P < 0.001). Figure 4A ). ZBTB33/KAISO was unaltered in the cell line panel.
The upregulation of five of the six tested KMTs including KHMT1C/ EHMT2 and KMT1B/SUV39H2 in PC-3 and the other CaP cells may co-operate with elevation of NCOR1 to either induce and/or sustain inappropriate levels of H3K9me2. In turn, this repressive histone modification attracts the HP-1 complex and leads to elevated local DNA methylation associated with stable gene silencing and/or transrepression in response to 1α,25(OH) 2 D 3 treatment. We examined this possibility by examining gene regulation in response to the cotreatment of 1α,25(OH) 2 D 3 and the KMT inhibitor chaetocin, compared with inhibitor alone (42, 43) . Supporting a role for deregulated KMT activity to distort transcription, this cotreatment with chaetocin reduced the 1α,25(OH) 2 D 3 -transrepression of CDKN1A in PC-3 cells ( Figure 4B ).
Changes in DNA methylation on the CDKN1A promoter in response to 1α,25(OH) 2 D 3
To examine how the basal and regulated patterns of CpG methylation differed between the two cell models, we used MAQMA assays. This approach allowed measurement of the DNA methylation at multiple points along the CDKN1A promoter including regions that were within 300 nucleotides of the center of the three VDR binding regions and the TSS.
These studies revealed that the basal methylation patterns differed significantly and very specifically between the two cell models. There is a large CpG island in the area surrounding the TSS and there were 19 CpGs that were informative with the MAQMA. Most showed very low levels of methylation (0-10%) with no difference between the cell lines. However, at CpG position K that is in close proximity to the TSS (−104 relative to TSS), shown in Figure 5A , we observed only 2% methylation in RWPE-1 but 28% in the non-responsive PC-3 cells. The three VDREs are outside the context of a CpG island but do contain individual CpG positions. At VDRE2 in both cell lines, the basal level of methylation was rather high with position E showing more methylation in RWPE-1 (99%) compared with PC-3 (77%), whereas this was reversed at position G (66% in RWPE-1 and 86% in PC-3). VDREs 1 and 3 have only two CpG positions each, but they show strong differences at specific methylation. Methylation at VDRE1 was found to be higher in the non-responsive PC-3 cells (positions H and I; ~35% in RWPE-1 and ~85% in PC-3) but the opposite was true for VDRE3 (positions A and B; ~90% in RWPE-1 and ~25% in PC-3).
In RWPE-1, following 1α,25(OH) 2 D 3 treatment, there were regions near the TSS and the VDREs where DNA methylation levels changed. In particular, VDRE2 showed marked and progressive loss of methylation 1 and/or 4 h after treatment in positions D and G, going from 85% to 14% at positions D after 4 h and from 66% to 11% at position G. In contrast, in the non-responsive PC-3 cells, there was little to no methylation change in VDRE2. Position D went from 89% to 63%, which is a much smaller reduction than seen in RWPE-1, whereas there was no change at position G ( Figure 5B ). VDRE1 showed a small reduction of methylation in RWPE-1 cells after 1 h of treatment at position H that reverted back by 4 h (34%, to 17%, to 34%). Whereas in PC-3 cells, at position H the higher basal level of methylation remained with only a slight reduction at 4 h of treatment from 80% to 65%. Regardless, the relatively high level of methylation in PC-3 at VDRE1 remained in comparison with RWPE-1. Very little change in methylation patterns were observed at VDRE3 in RWPE-1 cells, but in the relatively undermethylated PC-3 cells, we observed an increase in methylation at 1 h at both positions A and B, followed by a reduction of methylation at 4 h. The TSS at position J also showed increased methylation driven by 1α,25(OH) 2 D 3 treatment in PC-3 cells.
These findings were consistent with the changes in the binding of NCOR1 following 1α,25(OH) 2 D 3 treatment in PC-3 versus RWPE-1. The basal levels of DNA methylation may represent the probability of NCOR1 association. Thus, at position K at the TSS, there is elevated basal CpG methylation in PC-3 cells and was accompanied by the ligand-induced enrichment of NCOR1 at the TSS. Furthermore in PC-3 cells, ligand-induced enrichment of NCOR1 at VDRE2 at 0.5 h and 2 h was accompanied with sustained DNA methylation at positions D and G. Also in PC-3 cells, immediate ligand-induced enrichment of NCOR1 at VDRE3 was accompanied by increased DNA methylation at regions A and B at 1 h. Finally, NCOR1 ligand-induced enrichment was apparent in PC-3 cells at multiple time points at the TSS and was accompanied by increased DNA methylation at position J.
Discussion
The current study was undertaken to investigate epigenetic mechanisms that distort transcriptional responses in cancer using the VDR as a model transcription factor. The VDR governs and influences antimitotic and prodifferentiation transcriptional programs, and these actions are distorted in prostate cancer cells (44) . Therefore, dissecting the 1α,25(OH) 2 D 3 -recalcitrant phenotype is also of potential clinical significance. To address this aim, we considered two components of epigenetic regulation. First, we examined whether the corepressor protein NCOR1 was differentially recruited to target genes that are known to regulate these antimitotic transcriptional programs, in particular we focused on CDKN1A (encodes p21 (waf1/cip1) ). Second, we investigated to what extent the altered regulation of genes was also reflected by differential basal and regulated patterns of DNA methylation.
As a starting point to these questions, the current study undertook a comprehensive time-resolved approach to reveal differential mRNA regulation of a panel of VDR target genes in three different prostate cell models. These studies revealed that 1α,25(OH) 2 D 3 -regulated expression was attenuated and repressed in models with reduced and recalcitrant responses to the antimitotic actions of 1α,25(OH) 2 D 3 . Compared with non-malignant RWPE-1 cells, in most cases, the magnitude of 1α,25(OH) 2 D 3 -stimulated gene regulation in the isogenic transformed RWPE-2 cells was reduced. These patterns in mRNA expression in RWPE-1 cells were comparable with those reported previously that associated with cyclical patterns of protein expression (2) . In PC-3 cells, the cyclical mRNA transactivation was abolished and in many cases replaced by transrepression.
Gene targets were also regulated selectively through the cell cycle in RWPE-1 cells, with G 1 being the most transcriptionally permissive phase, and this was also suppressed in PC-3 cells. Previously, we established in RWPE-1 that epigenetic mechanisms significantly favored VDR regulation in G 1 (2) , an event that has also been demonstrated for AR signaling (18) . We have also established altered expression of corepressors through the cell cycle between RWPE-1 and PC-3 cells (17) . Thus, the regulation of genes observed in bulk culture may well represent a subset of cells, in G 1 , that are maximally responsive. The suppressed gene regulation in 1α,25(OH) 2 D 3 -recalcitrant cells may reflect the actions of different corepressor components within separate phases of the cell cycle. Similarly, the small magnitudes of regulation (and dysregulation) of mRNA are probably to translate to a greater collective impact on cell-cycle regulatory networks and therefore phenotypes. 
Corepressor recruitment in prostate cancer
Building on these studies, we examined the binding of NCOR1 following VDR activation and revealed that 1α,25(OH) 2 D 3 induced greater NCOR1 association on the CDKN1A promoter in PC-3 cells, compared with RWPE-1 cells. Thus, NCOR1 was sustained and enriched at all three VDR binding sites to different extents and at different time points. Probably, reflecting looping events, the TSS showed sustained NCOR1 enrichment throughout the time course (45) .
We reasoned that the consequences of this enhanced and sustained recruitment would be a critical loss of H3K9ac at, and around, the VDRE binding regions and may in turn allow KMT enzymes to modify this lysine and sustain H3K9me2 levels. Supportively, in other non-cancer systems, increased targeting of KMT1A/SUV39H1 to the CDKN1A promoter sustained H3K9me2 (43, 46) . We therefore undertook a survey of multiple KMTs in a broad panel of prostate cell lines and revealed that five out of six KMTs were commonly overexpressed, including KHMT1C/ EHMT2 and KMT1B/SUV39H2. Cotreatment with the KMT inhibitor, chaetocin, reversed the gene transrepression in PC-3 cells supporting a role for these enzymes to alter the patterns of CDKN1A regulation.
Given that H3K9me2 levels can attract the machinery that drives DNA CpG methylation, we examined the basal and regulated DNA methylation patterns on the CDKN1A promoter in RWPE-1 and PC-3 cells. Significantly, both the basal and 1α,25(OH) 2 D 3 -regulated CpG methylation differed in a position-specific manner. Basal differences were evident, but more surprisingly 1α,25(OH) 2 D 3 treatment resulted in clear changes in the site-specific methylation in both models. For example, VDRE2 and the TSS contained CpG regions that were either de-methylated or unchanged in RWPE-1 cells but in PC-3 cells they either remained highly methylated or displayed increased methylation. Again, these findings also reflected our earlier work in RWPE-1 cells that identified VDRE2 as a critical to the activation of CDKN1A (2). In parallel, Carlberg et al. revealed that VDRE2 was a key responsive element involved in chromatin looping and gene activation (45) . Taken together, these findings supported the concept that inappropriate NCOR1 recruitment coupled with elevated levels of key KMTs such as KMT1B/SUV39H2 can sustain H3K9me2 levels that in turn attract the DNA methylation machinery, for example through HP-1, and sustain transcriptional silencing by inducing DNA methylation (6,13)(reviewed in (9)). A parallel inference may also be that this mechanism could contribute to the transrepression by the VDR of targets such as c-MYC (47) and therefore it is tempting to speculate that gene regulation behavior reflects how sustained the interactions are with corepressors such as NCOR1 and NCOR2/ SMRT.
It is now over 30 years since the initial reports demonstrated the anticancer actions of 1α,25(OH) 2 D 3 (48) (49) (50) . Following these studies, antiproliferative effects were demonstrated in a wide variety of cancer cell lines, including those from prostate (51-54), as well as xenograft and transgenic CaP models (55, 56) . As the anticancer effects of the ligand emerged, large-scale epidemiological studies found inverse associations between circulating 25OHD 3 and cancer risk and advanced disease (57) (58) (59) (60) (61) (62) (63) (64) (65) . However, although in vitro, in vivo and epidemiological data support links between replete VDR signaling, growth restraint and broad anticancer activities, clinical exploitation of this receptor has been limited. A significant impediment to translation remains the inability to predict accurately which patients will respond to either chemoprevention or chemotherapy strategies centered on vitamin D compounds. The mechanisms that drive this resistant phenotype are often illusive and probably involve multiple aspects of disruption. Key mechanisms include gene amplification of the 1α,25(OH) 2 D 3 metabolizing enzyme CYP24A1 (66) and repression of the VDR by more general repressors such as SNAIL (67) . The process of inappropriate corepressor recruitment leading to stable gene silencing also contributes to this phenotype and in particular may shed light on why the VDR and other nuclear receptors are often expressed in non-malignant and retained in malignant prostate epithelial cells (17) .
The differential recruitment of corepressors also addresses another ambiguity in their cancer biology. Increased NCOR1 and NCOR2/SMRT expression occurs in breast and bladder cancer associated with suppressed responsiveness of nuclear receptors that exert mitotic restraint, such as VDR and PPARα/γ (17, (19) (20) (21) (22) (23) (24) (25) . In contrast, other studies have shown that downregulated NCOR1 and NCOR2/SMRT enhanced AR transcriptional programs in CaP (27, 28) . Thus, in CaP, there appears to be conflicting pressures on the expression of corepressor expression. Instead, we propose that gene-specific recruitment may be at least as significant as changes in expression.
Nuclear receptors display a range of distributions between the cytoplasm and the nucleus. In the absence of ligand, steroidal receptors such as the AR are cytoplasmic, whereas others including the VDR are resident more predominantly in the nucleus. The conflicting pressures on corepressor function in prostate cancer maybe resolved by considering their location within the cell, and on chromatin. By being inappropriately retained on nuclear receptors resident in the nucleus, they may distort a transient epigenetic process, the control of H3K9 methylation status, to favor a more stable epigenetic event, namely DNA methylation. Thus, the increased recruitment of corepressor association may convert a transient epigenetic silencing process, which is part of the normal nuclear receptor-transcriptional cycle, into a stable and heritable epigenetic event. The consequences of this could therefore be the targeted methylation of genes where NCOR1 and other corepressors are recruited by the VDR, or other nuclear resident transcription factors.
Therefore, these receptors may provide a route for the silencing of critical transcriptional programs by selective NCOR1 recruitment and thereby allow CaP cells to escape mitotic restraint. Given the role for corepressors to sequestrate and direct histone deacetylases and methyltransferases, these findings have important implications for the effective targeting of epigenetic therapies during CaP progression with current and next-generation epigenetic drugs. 
